Blood products group CSL has reported a net profit of $US1.2 billion, an increase of 19%. The group announced a final dividend of was US52c which was in line with estimates. Capital management was amongst the positive factors. With the current share buy almost complete, CSL is considering returning more capital to investors. The outlook for earnings growth was as expected, with a profit forecast to grow by 10% in 2014. CSL will pay an unfranked final dividend of US 52 cents on the 4th of October. The total annual dividend of $US1.02 is an 18 per cent increase compared to the previous year. For more information visit investing.commsec.com.au/reportingseason
Please sign in to comment on this wire.